A recent multinational study of 602 patients with advanced liver cancer showed promising results. Half of the patients were given two tablets a day of a drug called sorafenib, while the other half received a placebo. On average, those who took the sorafenib survived much longer than those who received the placebo. Sorafenib zeros in on malignant cells and cuts off the blood supply feeding the cancerous tumor.
Liver cancer is notoriously resistant to modern cancer treatments such as chemotherapy. Over 19,000 Americans are diagnosed with liver cancer annually. This study gives hope to the millions worldwide who have this deadly disease.
Click here for the full article